Blood test may predict nausea in breast cancer patients

NCT ID NCT07465172

First seen Mar 16, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study looks at whether a hormone called GDF-15, measured in the blood, can predict which breast cancer patients will experience severe nausea and vomiting from the drug T-DXd. Researchers will track 150 patients starting T-DXd treatment and compare their GDF-15 levels with side effects. The goal is to find a way to identify at-risk patients early, so doctors can better manage these side effects in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Lake Macquarie Private Hospital

    Newcastle, New South Wales, 2290, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Okayama University Hospital

    Okayama, 700-8558, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.